NASDAQ · VANI

Vivani Medical, Inc.. (DE)

$1.28 -$0.11 (-7.91%) 1D Market open

Key Metrics

$119.87M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 1.45
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 8
    The stock moved +18.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 8
  • Apr 16
    The stock moved +14.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 16
  • Mar 30
    From its Jan 29 high, the share price fell 38%.

    Peak close $1.51 on Jan 29; trough close $0.94 on Mar 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -38%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$119.87M
Enterprise value$48.22M
Shares outstanding86.2M
52-wk range$0.92 – $1.92
Avg volume · 20D353.6K
Net cash $71.65M
Book value / share$0.84
IndustryElectromedical & Electrotherapeutic Apparatus
ExchangeNASDAQ
About Vivani Medical, Inc.. (DE)
IPO dateAug 31, 2022
Employees36

Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of m…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio20.61
Quick ratio
Debt / equity0.03
Debt / EBITDA
Net cash $71.65M
Working capital$71.78M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2021-06-30 · computed by TickerWolf from SEC filings